Monday 20 July, 18:00 – 19:00 CEST
How can liver transplant patients enjoy an improved quality of life whilst being compliant with their therapy and avoiding viral infection?
During the COVID-19 pandemic, transplant patients and clinicians have been faced with considerable challenges. In particular, immunosuppressed HBV liver transplant patients are required to receive on-going therapy to prevent HBV recurrence. To achieve comprehensive protection, it is recommended that patients, particularly those in the high-risk category, are administered a combination of antivirals and Hepatitis B-specific hyperimmunoglobulins (HBIG).
The intravenous and intramuscular administration of HBIG requires HBV liver transplant patients to visit the hospital and infusion ward, meaning patients are exposed to the risk of contracting COVID-19 through increased contact with both healthcare professionals, care-givers and other patients.
Subcutaneous administration offers an alternative option that allows the patient to administer HBIG by themselves at home. This ensures the patient receives essential medication without coming in to contact with others, which both reduces the patients’ risk of exposure to COVID-19 and allows healthcare professionals to focus on COVID-19 patients. Moreover, with therapy from home, comes greater flexibility and freedoms which increases compliance and quality of life for the patient.
ESOT, together with BIOTEST, is organising this webinar to discuss how immunosuppressed transplant patients can be kept safe from HBV-reinfection and COVID-19, whilst enjoying an improved quality of life, through self-administration of subcutaneous HBIG at home.
Join us and panellists Professor Jean Hardwigsen and Dr Riccardo Volpesto learn more.